Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-329-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
No data regarding toxicity to reproduction is provided according to column 2, section 8.7.1 of Annex VIII, as a reliable and adequate pre-natal developmental toxicity study performed with an analogue source substance is available and data are read-across.
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
No data regarding toxicity to reproduction is provided according to column 2, section 8.7.1 of Annex VIII, as a reliable and adequate pre-natal developmental toxicity study performed with an analogue source substance is available and data are read-across.
Effects on developmental toxicity
Description of key information
No data are available for the target substance Sulfuric acids, C9-11-iso-C10 rich, alkyl esters, sodium salt. Therefore, read-across from structural analogue substances has been applied.
OECD 414, rat, developmental toxicity, oral: not teratogenic, no effect on development
Maternal: NOAEL = 250 mg/kg bw/day; LOEL > 250 mg/kg
bw/day
Developmental: NOAEL = 250 mg/kg bw/day; LOEL > 250 mg/kg bw/day
Read-across from source substance Sulfuric acid, mono-C12-14-alkyl esters, sodium salts (CAS 85586-07-8)
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- Partially natural parturition.
- GLP compliance:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- According to Guideline.
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Concentration in vehicle: 10%
- Analytical verification of doses or concentrations:
- yes
- Details on mating procedure:
- According to Guideline.
- Duration of treatment / exposure:
- Day 6-15 of gestation.
- Frequency of treatment:
- Once daily.
- Duration of test:
- Day 21 and Post parturition
- Dose / conc.:
- 63 mg/kg bw/day (nominal)
- Dose / conc.:
- 125 mg/kg bw/day (nominal)
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 20 females (15 for dissection; 5 for natural parturition)
- Control animals:
- yes, concurrent vehicle
- Maternal examinations:
- Acording to Guideline, except for parturition. Except of killing one day prior to the expected day of delivery, five of 20 dams were allowed to natural parturition before sacrifice.
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: Five mated rats from each of the treatment and ten from the control group were selected by random numbers for natural parturition. This enabled observations on litter size, weight and infant mortality to be recorded, together with any other observable postpartum expression of response to treatment for a period of 21 days (birth to weaning). - Fetal examinations:
- - External examinations: Yes
- Soft tissue examinations: Yes
- Skeletal examinations: Yes
- Head examinations: No - Statistics:
- Yes
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
At 500 mg/kg bw/day, the test substance produced maternal toxicity associated with severe diarrhoea, reduced food intake and reduced body weight gain. There was one death in this group and two animals were killed prior to full term. The survivors showed an increased number of intrauterine deaths and a reduction in live foetal body weight. These foetuses showed evidence of toxic retardation, with delayed ossification and also an increased incidence of supernumerary cervical ribs and shortened thoracic ribs. There were no gross external or visceral anomalies which could be attributed to treatment.
No maternal toxic effects were seen in the other treatment groups and there were no effects on live foetal numbers, body weight or crown-rump distance. There was no evidence of a specific external, gross visceral or skeletal defect which could be attributed to treatment.
There was no indication of a treatment effect on pups born by natural parturition and reared to weaning age of 21 days. - Dose descriptor:
- NOAEL
- Remarks:
- maternal
- Effect level:
- 250 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Basis for effect level:
- other: no toxic effects
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
Effects were only seen in the presence of maternal toxicity. - Dose descriptor:
- NOAEL
- Remarks:
- development
- Effect level:
- 250 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Basis for effect level:
- other: no toxic effects
- Developmental effects observed:
- no
- Conclusions:
- Treatment of pregnant rats with the test substance at 500 mg/kg bw/day induced a maternal toxic response and this was reflected in the conception which showed toxic retardation. At 250, 125 and 63 mg/kg bw/day, the test substance did not cause maternal toxicity or foetotoxicity and did not show teratogenic potential.
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- Lack of details on test substance, intervals in dose range
- GLP compliance:
- no
- Species:
- rat
- Strain:
- other: CD
- Details on test animals or test system and environmental conditions:
- According to guideline.
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on mating procedure:
- According to guideline.
- Duration of treatment / exposure:
- Day 6-15 p.c.
- Frequency of treatment:
- Daily
- Duration of test:
- Day 20
- Dose / conc.:
- 0.2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 600 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 20
- Control animals:
- yes, concurrent vehicle
- Maternal examinations:
- According to guideline.
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Fetal examinations:
- - External examinations: No data
- Soft tissue examinations: Yes
- Skeletal examinations: Yes
- Head examinations: No - Statistics:
- Yes.
- Details on maternal toxic effects:
- Maternal toxic effects:yes
- Dose descriptor:
- NOAEL
- Remarks:
- maternal
- Effect level:
- 300 mg/kg bw/day
- Based on:
- act. ingr.
- Basis for effect level:
- other: retarded body weight gain
- Dose descriptor:
- LOAEL
- Remarks:
- maternal
- Effect level:
- 600 mg/kg bw/day
- Based on:
- act. ingr.
- Basis for effect level:
- mortality
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
- Dose descriptor:
- NOAEL
- Remarks:
- developmental
- Effect level:
- > 600 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Basis for effect level:
- other: no significant higher incidences of malfurmations
- Abnormalities:
- no effects observed
- Developmental effects observed:
- no
- Conclusions:
- At 600 mg/kg bw no developmental toxicity was detected. Maternal toxicity was present at 600 mg/kg bw.
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- lack of details on test substance, intervals in dose range
- GLP compliance:
- no
- Species:
- rabbit
- Strain:
- New Zealand White
- Details on test animals or test system and environmental conditions:
- According to guideline.
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on mating procedure:
- According to guideline.
- Duration of treatment / exposure:
- Day 6-18
- Frequency of treatment:
- Daily
- Duration of test:
- Day 1-29
- Dose / conc.:
- 0.2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 600 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 13
- Control animals:
- yes, concurrent vehicle
- Maternal examinations:
- According to guideline.
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Fetal examinations:
- - External examinations: No data
- Soft tissue examinations: Yes
- Skeletal examinations: Yes
- Head examinations: No - Statistics:
- Yes.
- Details on maternal toxic effects:
- Maternal toxic effects:yes
- Dose descriptor:
- NOAEL
- Remarks:
- maternal
- Effect level:
- 300 mg/kg bw/day
- Based on:
- act. ingr.
- Basis for effect level:
- other: retarded body weight gain
- Dose descriptor:
- LOAEL
- Remarks:
- maternal
- Effect level:
- 600 mg/kg bw/day
- Based on:
- act. ingr.
- Basis for effect level:
- mortality
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
- Dose descriptor:
- NOAEL
- Remarks:
- developmental
- Effect level:
- > 600 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Basis for effect level:
- other: no significant higher incidences of malformations in a dose-response way
- Abnormalities:
- no effects observed
- Developmental effects observed:
- no
- Conclusions:
- No maternal toxicity and no developmental toxicity up to 300 and 600 mg/kg/day, respectively.
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Principles of method if other than guideline:
- Method: other
- GLP compliance:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- Age: 16 - 18 weeks
- Route of administration:
- oral: gavage
- Details on mating procedure:
- Virgin female rats were taken at random from a stock cage and recaged in groups of 3 with each of 15 virgin male rats of the same age and from the same colony. The dropping trays were examined each morning thereafter for ejected vaginal plugs, and when these were found the female rats were removed and individually examined for evidence of mating. Confirmation of mating was established by microscopically examination of the vaginal mucus for the presence of spermatozoa.
- Duration of treatment / exposure:
- Days 6 - 15 of gestation
- Frequency of treatment:
- daily
- Duration of test:
- Termination on Day 21 of gestation or up to weaning Day 21.
- Dose / conc.:
- 63 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 125 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 250 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 15 rats (10 for dissection, 5 for natural parturition)
- Control animals:
- yes
- Details on study design:
- negative control: saline
positive control: aspirin 250 mg/kg s.c. - Maternal examinations:
- -body weight: daily
-maternal food intake: daily - Ovaries and uterine content:
- - mean gravid uterus weight & mean weight of uterine tissue
- intrauterine mortality
- mean response per pregnancy - Fetal examinations:
- - mean foetal body weight, crown rump distance and mean placental weight
- % incidence of external and gross visceral observations of foetuses
- incidence of skeletal variants/anomalies of foetuses
- incidence and distribution of other anomalies
- post-partum mortalities
- mean body weight of pups (at birth and on days 7, 14 and 21)
- weaned of born
- incidence of external and gross visceral variations of pups
- incidence of skeletal variations of pups - Details on maternal toxic effects:
- Maternal toxic effects: yes
Details on maternal toxic effects:
General health: All animals at 500 mg/kg bw/day had diarrhoea, which continued until cessation of treatment. With successive treatments the passage of the cannula down the oesophagus became more difficult suggesting a dryness of the membranes, and the demeanour of the animals became more aggressive. Between the 4th and 8th dose 4 of the animals of this group died and 1 was sacrificed because of its condition. A further animal aborted on the 14th day of gestation having received 9 treatments. All the animals which died showed evidence of gastrointestinal irritation and diffuse haemorrhage of the stomach. In 3 instances there was also congestion of the lungs. Mean maternal body weight gain: Treatment with 500 mg/kg bw/day induced a significant (p = < 0.05) reduction in maternal body weight gain during the period of treatment. Food consumption: Rats treated with 500 mg/kg bw/day consumed significantly (p=<0.05) less food than controls Intrauterine mortality: No significant differences between treatment and control Mean response per pregnancy: Treatment did not adversely affect the pre- or post-implantation loss - Dose descriptor:
- NOAEL
- Remarks:
- maternal
- Effect level:
- 250 mg/kg bw/day
- Basis for effect level:
- other: diarrhoea, gastrointestinal irritation and diffuse haemorrhage of the stomach
- Dose descriptor:
- LOAEL
- Remarks:
- maternal
- Effect level:
- 500 mg/kg bw/day
- Basis for effect level:
- other: diarrhoea, gastrointestinal irritation and diffuse haemorrhage of the stomach
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
Foetal and placental size: The mean placental weight for male and female foetuses combined and considered separately were significantly lower in animals fed 500 mg/kg bw/day (p= 0.05). Incidence of gross variants/anomalies: No significant differences between treatment groups and control group Incidence of skeletal anomalies: No significant differences between treatment groups and control group Incidence of foetal variations, minor anomalies and major malformations: Malformations were found in 3 foetuses from dams treated with 500 mg/kg bw/day - protruding tongue, gross oedema and shortening of the pubic bone; agenesis of eyelids and cleft palate; unossified metatarsus and claw in left hind foot. The foetuses were all taken from separate pregnancies. A single live foetus with a malformation was also found after treatment with 250 mg/kg bw/day (hermi-centric lumbar centra with asymmetry and reduced ossification of the 6th lumbar arch and scoliosis) and 63 mg/kg bw/day (unossified and dumbbell shaped thoracic centrae associated with branched ribs) Rats allocated to natural parturition: Post-partum mortalities: No significant differences between treatment and controls. Incidence of skeletal defects in rat pups: No significant differences between treatment groups and control group. - Dose descriptor:
- NOAEL
- Remarks:
- developmental
- Effect level:
- >= 500 mg/kg bw/day
- Basis for effect level:
- other: no effects observed
- Abnormalities:
- no effects observed
- Developmental effects observed:
- no
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Principles of method if other than guideline:
- Method: other
- GLP compliance:
- no
- Species:
- rat
- Strain:
- Wistar
- Route of administration:
- oral: gavage
- Duration of treatment / exposure:
- Day 6 - 15 of gestation
- Frequency of treatment:
- daily
- Duration of test:
- termination on GD 21 or up to weaning day 21
- Dose / conc.:
- 112 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 225 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 450 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 675 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 15 females per dose group: 10 for dissection and 5 for natural parturition
- Control animals:
- yes, concurrent vehicle
- Dose descriptor:
- NOAEL
- Remarks:
- maternal
- Effect level:
- 225 mg/kg bw/day
- Basis for effect level:
- body weight and weight gain
- clinical signs
- Dose descriptor:
- LOAEL
- Remarks:
- maternal
- Effect level:
- 450 mg/kg bw/day
- Basis for effect level:
- body weight and weight gain
- clinical signs
- Dose descriptor:
- NOAEL
- Remarks:
- developmental
- Effect level:
- 675 mg/kg bw/day
- Based on:
- act. ingr.
- Basis for effect level:
- other: no effects observed
- Dose descriptor:
- LOAEL
- Remarks:
- develoopmental
- Effect level:
- > 675 mg/kg bw/day
- Based on:
- act. ingr.
- Basis for effect level:
- other: no effects observed
- Abnormalities:
- no effects observed
- Developmental effects observed:
- no
Referenceopen allclose all
Maternal effects:
General health: Treatment with 675 mg/kg bw/day
induced diarrhoea in 4/15 females
after the third dose day (day 9 of gestation)
Mean maternal body weight gain: the mean maternal body weight gain in rats
fed 675 mg/kg bw/day on days 6-10 and rats fed 450 mg/kg bw/day on days 10-15 of gestation
were significantly lower (p = < 0.05) than controls
Food consumption: no significant differences between treatment and control groups
Intrauterine mortality: no significant differences between treatment and control
Mean response per pregnancy: When data for live foetuses was analysed there
was significantly less (p=<0.05) live foetuses in the 675 mg/kg group
than the controls. This was not attributable, however, to a significant
decrease in viable female foetuses in this group, but purely a chance
occurrence of a high number of female foetuses in the controls.
Offspring:
Foetal and placental size: Only significant effect when data for the
separate males and females was analysed which revealed a significantly
lower (p= <0.05) mean placental weight for the male foetuses in the 450
mg/kg bw/day group
Incidence of gross variants/anomalies: No explanation could be given for
the incidence of macroscopically observed haemorrhage under the capsule
of the kidney in some foetuses in the 3 lower treatment groups (3.66% of
foetuses at 450 mg/kg bw/day; 3.73% at 225 mg/kg
bw/day; 4.95% at 112 mg/kg bw/day).
Incidence of skeletal anomalies: Analysis of the data relating to
vertebral and head variations/anomalies revealed a significant (p=<0.05)
increase in the foetuses from mothers treated with 112 mg/kg bw/day
Rats allocated to natural parturition
Post-partum mortalities: In the 675 mg/kg bw/day treatment group 5/6
pups were partially cannibalised during post-partum days 1-3 and all came
from a single litter. Two pups from a single litter were also cannibalised
in the 450 mg/kg bw/day treatment group.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 250 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
No data regarding developmental toxicity of Sulfuric acids, C9-11-iso-C10 rich, alkyl esters, sodium salt are available. Therefore, read-across from the structural analogue substance Sulfuric acid, mono-C12-14-alkyl esters, sodium salts (CAS 85586-07-8) has been applied in accordance with Regulation (EC) No 1907/2006 Annex XI 1.5 “Grouping of substances and read-across approach”. In Annex XI 1.5 it is given that a read-across approach is possible for substances whose physico-chemical, toxicological and ecotoxicological properties are likely to be similar or follow a regular pattern as a result of structural similarity. The AS reported within the AS read-across approach show structural similarity. The most important common structural feature of the source and target substances is the presence of a predominantly linear aliphatic hydrocarbon chain with a polar sulfate group, neutralized with a counter ion. This structural feature confers the surfactant properties of the alkyl sulfates. The surfactant property of the source and target substances in turn represent the predominant attribute in mediating effects on mammalian health. Therefore, the AS have similar physico-chemical, environmental and toxicological properties. The approach of grouping different AS for the evaluation of their effects on human health and the environment was also made by the OECD in the SIDS initial assessment profile [1] and by a voluntary industry programme carrying out Human and Environmental Risk Assessments (HERA [2]), further supporting the read across approach between structurally related AS.
Regarding developmental toxicity / teratogenicity one relevant key study with Sulfuric acid, mono-C12-14-alkyl esters, sodium salts (C12-14 AS Na, CAS 85586-07-8) and further supporting studies with structurally analogue read-across source substances Sodium dodecyl sulfate (C12 AS Na, CAS 151-21-3) and Sulfuric acid, mono-C16-18-alkyl esters, sodium salts (C16-18 AS Na, CAS 68955-20-4) are available.
In the developmental toxicity study which was chosen as key study C12-14 AS Na (CAS 85586-07-8) was administered orally by gavage to pregnant Wistar rats at dose levels of 0, 63, 125, 250 and 500 mg/kg bw/day once daily from Day 6 to 15 of gestation (Unilever, 1987). In summary, C12-14 AS Na (CAS 85586-07-8) induced maternal toxicity, indicated by body weight decrease, diarrhoea and increased mortality, when administered at doses of 500 mg/kg bw/day. Developmental toxicity could be seen by an increased number of intrauterine deaths, a decreased live foetal body weight and toxic retardation with delayed ossification and increased incidence of supernumerary cervical ribs and shortened thoracic rib at 500 mg/kg bw/day. Based on the available information the NOAEL for maternal toxicity and developmental toxicity is set at 250 mg/kg bw/day.
The purpose of the studies conducted by Palmer (1975a&b) was to assess the effects of orally administered C12 AS Na (CAS 151-21-3) on embryonic and foetal development in pregnant CD-rats and NZW-rabbits. In this study, C12 AS Na (CAS 151-21-3) was administered orally by gavage at dose levels of 0, 0.2, 2, 300 and 600 mg/kg bw/day once daily from Day 6 to Day 15 (rat) / Day 19 (rabbit) of gestation. In summary, the results of the study showed that repeated oral administration of C12 AS Na (CAS 151-21-3) to pregnant rats and rabbits did not cause symptoms of cumulative maternal toxicity up to a dose level of 300 mg/kg bw/day. There were no treatment-related foetal abnormalities at necropsy and no treatment-related effects in the reproduction data. Thus, based on the available information, the NOAEL for teratogenicity and developmental toxicity are assessed to be greater than 600 mg/kg bw/day.
The effect of C12 AS Na (CAS 151-21-3) on embryonic and foetal development was as well assessed by Unilever (1976c) in Wistar rats. The test substance was administered by gavage at dose levels of 0, 63, 125, 250 and 500 mg/kg bw/day once daily from Day 6 to 15 of gestation. No cumulative maternal toxicity was seen up to a dose level of 250 mg/kg bw/day. At 500 mg/kg bw/day dams showed significant decreased body weight and food consumption together with corresponding clinical signs like diarrhoea. No treatment-related foetal abnormalities or effects in the reproduction data were observed at 500 mg/kg bw/day. Thus, the NOAEL for teratogenicity and developmental toxicity are assessed to be greater than 500 mg/kg bw/day.
Finally, embryonic and foetal development was examined after administration of C16-18 AS Na (CAS 68955-20-4; Unilever, 1978). The alkyl sulfate was administered by gavage at dose levels of 0, 112, 225, 450 and 675 mg/kg bw/day once daily from Day 6 to 15 of gestation. At 450 mg/kg bw/day and higher dams showed significant decreased body weight gain together with diarrhoea. No treatment-related foetal abnormalities or effects in the reproduction data were observed at 675 mg/kg bw/day. Thus, the NOAEL for teratogenicity and developmental toxicity are assessed to be greater than 675 mg/kg bw/day.
Conclusion
In the key developmental toxicity study with the analogue substance Sulfuric acid, mono-C12-14-alkyl esters, sodium salts (CAS 85586-07-8), developmental effects were noticed, which however occurred at a dose level which clearly was found to be toxic to the dams. Thus the findings do not provide any evidence for the test item to be potentially toxic to development and/or teratogenic. Thus, AS, including the target substance Sulfuric acids, C9-11-iso-C10 rich, alkyl esters, sodium salt are considered to be not teratogenic.
[1] SIDS initial assessment profile, (2007); http://www.aciscience.org/docs/Alkyl_Sulfates_Final_SIAP.pdf
[2] (HERA Draft report, 2002); http://www.heraproject.com/files/3-HH-04-%20HERA%20AS%20HH%20web%20wd.pdf
Justification for classification or non-classification
The available data on reproductive toxicity do not meet the criteria for classification according to Regulation (EC) No. 1272/2008 (CLP) and are therefore conclusive but not sufficient for classification.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.